Beyondspring (BYSI) news
Recent news
JSE: BYI - Results for the six months ended 31 August 2026 and declaration of cash dividend
AInvest Wire · 2d agoBeyondSpring Inc: Entered into open market sale agreement under which co may offer and sell up to 9.2 mln ordinary shares
AInvest Wire · Sep 29, 2026BeyondSpring - Sells majority equity interest in Chinese subsidiary to fund Dublin-4 trial in China
BeyondSpring Inc. (NASDAQ: BYSI) has announced the sale of a portion of its equity stake in its Chinese subsidiary, Wanchunbulin, to fund the DUBLIN-4 clinical trial in China. The transaction, part of a broader strategic partnership with Jiangsu Hengrui Pharmaceuticals, involves Hengrui receiving…
AInvest Wire · Sep 29, 2026BeyondSpring - Retains global rights to plinabulin outside Greater China
BeyondSpring Inc. (NASDAQ: BYSI) retains global rights to its lead compound, Plinabulin, outside of Greater China, maintaining strategic control over its development and commercialization in key international markets. The company continues to advance Plinabulin through multiple clinical trials,…
AInvest Wire · Sep 29, 2026BeyondSpring announces FDA fast track designation for Plinabulin in post-ICI non-squamous NSCLC and strategic transaction to advance global phase 3 Dublin-4 trial toward planned interim analysis
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.